HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients

Peng, Cheng Yuan; Hsieh, Tao-shih; Hsieh, Tsai Yuan; Tseng, Kuo‐Chih; Lin, Chun-Han; Su, Tung‐Hung; Tseng, Tai Chung; Lin, Hans Hsienhong; Wang, Chia‐Chi; Kao, Jia‐Horng

doi:10.1016/j.jfma.2013.10.023

Cited by 12 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While our results coincide with data from Far east and Middle of Asia [18][19][20][21][22]. Chang et al from Taiwan, showed in their 5 year follow up study of 146 Entecavir treated patients that 94% (88/94) had HBV-DNA <300 copies/mL and 80% (78/98) had normalized ALT levels [19].…”

Section: Discussionsupporting

confidence: 91%

“…These findings coincide with Ting and his colleagues who 23% achieved HBeAg sero-conversion and 1.4% HBsAg sero-conversion during the study [19]. Also similar results were shown by Cheng-Yuan Peng et al, from Taiwan [21]. In addition, they found that complete virological response at 6 months is a favorable predictive of HBeAg loss at 2 years of Entecavir therapy.…”

Section: Discussionsupporting

confidence: 90%

“…In addition, they found that complete virological response at 6 months is a favorable predictive of HBeAg loss at 2 years of Entecavir therapy. Therefore, measurement of serum HBV-DNA level at 6 months of Entecavir therapy is optimal to predict HBeAg loss at 2 years of therapy in HBeAg-positive CHB patients [21]. Data from Japan, by Atsushi and his colleagues assured the antiviral potency and viral resistance rate after 4 years of continuous Entecavir treatment in patients with CHB infection.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Retrospective-Prospective Study on Efficacy & Safety of Entecavir in Chronic Hepatitis B West Asian Patients with Genotype D

Akrouf¹,

Gad²,

Ibraheem³

et al. 2017

J Clin Infect Dis Pract

View full text Add to dashboard Cite

Aim: To assess the long term efficacy and safety of Entecavir in the treatment of CHB in Asian-Arabic patients with genotype D, for both nucleoside-naïve as well as experienced, comparing HBeAg positive and negative group. Methods:This study included 70 CHB consecutive patients who were maintained on Entecavir for at least 36 months retrospectively and followed up prospectively every 3 months for a total of 18 months, at 2 centers in Kuwait (October 2012 and April 2014).Results: It showed that 23 (32.8%) were HBeAg +ve. All were found to be HBV genotype D, 47.1% naive, 22 (31.4%) females, with a mean age of 42.9 ± (13), 14 (20%) cirrhotic and 1(1.4%) decompensated. There were no significant differences in the pre-treatment HBV-DNA level among HBeAg+ve and HBeAg-ve group, with a mean± SD log 10 of 7.9 ± 5.4 and 7.4 ± 5.0 respectively (P=0.237). There was a significant viral load reduction in both groups after 6 months of treatment with Entecavir. The reduction was more pronounced in the HBeAg-ve compared to HBeAg +ve group. In HBeAg +ve, 19 patients (82.61%) had complete HBV-DNA suppression after a median period of 7 month, while in HBeAg -ve group; all (100%) had complete HBV-DNA suppression after a median period of 5 month duration (P<0.05). None showed primary non response to Entecavir in both groups. In the HBeAg-ve group; one (2.13%) had HBsAg loss at 45 month compared to non in HBeAg+ve group (P<0.001), while in the HBeAg+ve group; 5 (21.74%) showed HBeAg clearance after a median of 16 month during Entecavir treatment. Multivariate analysis identified HBeAg negative status, pre-treatment as the only independent factor affecting complete viral suppression on Entecavir treatment. The drug showed 100% safety, as there were no serious adverse events throughout 54 month of follow up. None showed hepatic decompensation, HCC or need for liver transplantation during follow up. Also, there was no reported death throughout study period in both groups. Conclusions:In real life data; long term Entecavir treatment for up to 54 months in West Asian CHB patients, with genotype D suppressed HBV-DNA to an undetectable level in 100% of HBeAg-ve, compared to 82% in HBeAg +ve group. Entecavir is considered an effective and safe choice on long term use for treatment CHB patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective-Prospective Study on Efficacy & Safety of Entecavir in Chronic Hepatitis B West Asian Patients with Genotype D

Akrouf¹,

Gad²,

Ibraheem³

et al. 2017

J Clin Infect Dis Pract

View full text Add to dashboard Cite

show abstract

“…During TDF treatment, non-detectable serum HBV DNA at week 24 is the strongest predictor for an optimal response at 2 years (19). Similar results have been reported with ETV therapy (20). Based on the evidence supporting, the predictive value of on-treatment kinetics, a 'road map' algorithm of practical guidelines recommending HBV DNA measurements at weeks 12 and 24 has been proposed (21).…”

Section: Monitoring Therapymentioning

confidence: 64%

HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients

Martinot–Peignoux

Asselah

Marcellin

2014

Liver International

View full text Add to dashboard Cite

Hepatitis B surface antigen (HBsAg) levels in serum have been shown to reflect active intrahepatic covalently closed circular DNA (cccDNA) and to have additional value as a marker of on-treatment efficacy. In the past few years, immunoassays to quantify HBsAg have been developed to monitor HBsAg kinetics during treatment. Although HBsAg quantification cannot replace HBV DNA measurement in clinical practice, the combined use of HBsAg quantification and HBV DNA measurements could help predict treatment outcome. One of the most important results of the studies in this new marker is that a decline in HBsAg titres during pegylated-interferon (PEG-IFN) treatment is a strong predictor of response so that a 'week 12 stopping rule' could be established for both Hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients. However, the positive predictive value (PPV) for a sustained viral response (SVR) remains low. The role of HBsAg measurements during nucloes(t)ides analogue (NAs) treatment is unclear. It may be a useful marker for stopping NAs by limiting the chance of relapse or for add-on strategies. Monitoring serum HBsAg levels in chronic hepatitis B (CHB) patients during treatment may provide significant complementary information to HBV DNA measurements. Key Points• Serum hepatitis B surface antigen (HBsAg) level reflects the transcriptional activity of covalently closed circular DNA in the liver.

show abstract

“…Furthermore, recent studies have suggested that earlier suppression of the HBV DNA to an even lower level during the course of antiviral therapy has a higher likelihood of resulting in improved clinical outcomes [15]. For example, the highest rates of HBeAg seroconversion and lowest rates of drug resistance were observed in a subgroup of patients who achieved serum HBV-DNA levels \2000 IU/mL within the first 6 months of lamivudine (LAM) treatment [16].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan

Lin¹,

Hsieh

Tseng

et al. 2015

Hepatol Int

Self Cite

View full text Add to dashboard Cite

show abstract

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients

Cited by 12 publications

References 22 publications

Retrospective-Prospective Study on Efficacy & Safety of Entecavir in Chronic Hepatitis B West Asian Patients with Genotype D

Retrospective-Prospective Study on Efficacy & Safety of Entecavir in Chronic Hepatitis B West Asian Patients with Genotype D

HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients

Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan

Contact Info

Product

Resources

About